Patients' Perspectives on Early Liver Transplantation in Alcohol‐Related Liver Disease

Eric Wong, Paul D. Mullins, Jean‐Philippe Wallach, Eric M. Yoshida, Sigfried R. Erb, Jo‐Ann Ford, Charles H. Scudamore, Vladimir Marquez – 17 June 2019 – Liver transplant programs in Canada require a period of 6 months of abstinence from alcohol before considering a patient with liver disease secondary to alcohol for transplantation.

Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development

Justin D. Schumacher, Bo Kong, Jason Wu, Daniel Rizzolo, Laura E. Armstrong, Monica D. Chow, Michael Goedken, Yi‐Horng Lee, Grace L. Guo – 17 June 2019 – Farnesoid X receptor (FXR) induces fibroblast growth factor 15 (FGF15; human ortholog FGF19) in the gut to potently inhibit bile acid (BA) synthesis in the liver. FXR activation in hepatic stellate cells (HSCs) reduces liver fibrosis (LF). Fgf15–/– mice develop attenuated LF, but the underlying mechanisms for this protection are unclear.

Transient Cold Storage Prior to Normothermic Liver Perfusion May Facilitate Adoption of a Novel Technology

Carlo D. L. Ceresa, David Nasralla, Christopher J. E. Watson, Andrew J. Butler, Constantin C. Coussios, Keziah Crick, Leanne Hodson, Charles Imber, Wayel Jassem, Simon R. Knight, Hynek Mergental, Rutger J. Ploeg, Joerg M. Pollok, Alberto Quaglia, A. M. James Shapiro, Annemarie Weissenbacher, Peter J. Friend – 17 June 2019 – Clinical adoption of normothermic machine perfusion (NMP) may be facilitated by simplifying logistics and reducing costs. This can be achieved by cold storage of livers for transportation to recipient centers before commencing NMP.

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma

Jean‐Charles Nault, Yoann Martin, Stefano Caruso, Théo Z. Hirsch, Quentin Bayard, Julien Calderaro, Cecile Charpy, Christiane Copie‐Bergman, Marianne Ziol, Paulette Bioulac‐Sage, Gabrielle Couchy, Jean‐Frédéric Blanc, Pierre Nahon, Giuliana Amaddeo, Nathalie Ganne‐Carrie, Guillaume Morcrette, Laurence Chiche, Christophe Duvoux, Sandrine Faivre, Alexis Laurent, Sandrine Imbeaud, Sandra Rebouissou, Josep M.

Vessels Encapsulating Tumor Clusters (VETC) Is a Powerful Predictor of Aggressive Hepatocellular Carcinoma

Salvatore Lorenzo Renne, Ha Young Woo, Sarah Allegra, Noemi Rudini, Hirohisa Yano, Matteo Donadon, Luca Viganò, Jun Akiba, Hye Sun Lee, Hyungjin Rhee, Young Nyun Park, Massimo Roncalli, Luca Di Tommaso – 17 June 2019 – We investigated the clinical significance of a vascular growth pattern of hepatocellular carcinoma (HCC), the vessels that encapsulate tumor clusters (VETC), previously linked to HCC metastatic dissemination.

Rural‐Urban Differences in In‐Hospital Mortality Among Admissions for End‐Stage Liver Disease in the United States

Katherine H. Ross, Rachel E. Patzer, David Goldberg, Nicolas H. Osborne, Raymond J. Lynch – 17 June 2019 – Access to quality hospital care is a persistent problem for rural patients. Little is known about disparities between rural and urban populations regarding in‐hospital outcomes for end‐stage liver disease (ESLD) patients. We aimed to determine whether rural ESLD patients experienced higher in‐hospital mortality than urban patients and whether disparities were attributable to the rurality of the patient or the center.

Development of Capsular Fibrosis Beneath the Liver Surface in Humans and Mice

Steven Balog, Yuchang Li, Tomohiro Ogawa, Toshio Miki, Takeshi Saito, Samuel W. French, Kinji Asahina – 17 June 2019 – Glisson's capsule is the connective tissue present in the portal triad as well as beneath the liver surface. Little is known about how Glisson's capsule changes its structure in capsular fibrosis (CF), which is characterized by fibrogenesis beneath the liver surface.

LiverLearning®: Clinical Hepatology Update Conference 2019

** VIEW ONLY CONTENT . The Clinical Hepatology Update 2019 enduring course will be available soon. It will be available under the "On-Demand Accredited Activities". ** The Clinical Hepatology Update conference is designed for all medical professionals who manage care for patients with liver disease, including nurse practitioners, physician assistants, RNs, primary care physicians, medical students and GI or hepatology trainees. The conference will provide an update and review of the evolving practices in the clinical management of liver diseases.

Subscribe to